MMP9 and bronchopulmonary dysplasia: In addition to IGF-1/IGFBP3 interactions, defining how the regulatory mediators IFNγ, PAPP-A, Ang2, MMP9, IP-9, and IP-10 intersect in BPD and ROP may promote the development of new therapies that simultaneously target the development of both diseases while enhancing or allowing normal development to progress (Figure 3).